Eloise Chapman‐Davis

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma

Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal et al. · JAMA Oncology · 2019 · 533 citations · Full text

Racial and Ethnic Disparities in Genetic Testing at a Hereditary Breast and Ovarian Cancer Center

Eloise Chapman‐Davis, Zhen Ni Zhou, Jessica Fields et al. · Journal of General Internal Medicine · 2020 · 148 citations · Full text

Ethnicity, Ethnic Disparities, Genetic Testing +12

TOPACIO/Keynote-162 (NCT02657889): A phase 1/2 study of niraparib + pembrolizumab in patients (pts) with advanced triple-negative breast cancer or recurrent ovarian cancer (ROC)—Results from ROC cohort.

Panagiotis A. Konstantinopoulos, Steven Waggoner, Gregory A. Vidal et al. · Journal of Clinical Oncology · 2018 · 138 citations

Roc Cohort, Breast Oncology, Immunology +22

Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer

Melissa K. Frey, Annie E. Ellis, Kristen Zeligs et al. · American Journal of Obstetrics and Gynecology · 2020 · 120 citations · Full text

Treatment of nonmetastatic and metastatic low-risk gestational trophoblastic neoplasia: Factors associated with resistance to single-agent methotrexate chemotherapy

Eloise Chapman‐Davis, Anna V. Hoekstra, Alfred Rademaker et al. · Gynecologic Oncology · 2012 · 100 citations

Surgical Oncology, Medicine, Metronomic Therapy +5